VENTRICULAR MURAL THROMBUS IN PATIENT WITH LEFT VENTRICULAR ANEURYSM AFTER MYOCARDIAL INFARCTION

Makharynska O. S.¹, Lisogorska O. V.², Oktiabrova I. I.¹, Adu Albert Asare¹
¹ V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
² Kharkiv city clinical multi-field hospital No 25, Kharkiv, Ukraine

On the example of the clinical case of newly diagnosed mural thrombus in patient with post ST-elevation myocardial infarction chronic aneurysm formation, probable risk of further tromboembolism and anticoagulation benefit was discussed. Recommendations on lifestyle modification and medicament treatment tactics are described for prevention of new mural thrombi formation.

KEY WORDS: STEMI, mural thrombus, anticoagulation, risk, ventricular aneurism

INTRODUCTION

Left ventricular (LV) thrombus formation is a frequent complication in patients with acute anterior myocardial infarction (MI), occurring in at least 5 % of patients. Left ventricular thrombus is associated with increased risk of embolism. [1]. In the context of STEMI, prolonged ischemia results in subendocardial and endothelial injury and increased concentration of procoagulant factors, whereas akinetic areas of necrotic myocardium lead to blood stasis, especially at the LV apex [2]. Two-dimensional transthoracic echocardiography is the most effective diagnostic technique in this setting and can be quickly performed at the bedside but can lead to misdiagnoses due to difficult echo windows,
artificial, or the misinterpretation of LV trabeculations or chordae. [3]. In a recent article by Wada et al [4] was demonstrated the excellent diagnostic power of echo contrast for the diagnosis of LV thrombus in 392 patients with anterior MI. Echo contrast had 100% sensitivity and specificity compared with left ventriculography and/or multidetector computed tomography used as gold standard [5]. Anticoagulation therapy reduces both risks of thrombus formation and subsequent embolization, but leads to increased risk of bleeding. [6] Therefore, accurate detection and exclusion of LV thrombus in patients with coronary artery disease (CAD) are very important [7]. In observational studies and meta-analyses, anticoagulant therapy is recommended in order to minimize embolization risk. An oral vitamin K antagonist, warfarin, has been being used as an anticoagulant for this purpose for a long period of time. New oral anticoagulants (dabigatran, rivaroxaban, apixaban, etc.) were found to be non-inferior or superior compared to warfarin in prevention of thromboembolism in patients with nonvalvular atrial fibrillation [8].

**OBJECTIVE EXAMINATION**


**LABORATORY AND INSTRUMENTAL TESTS**

Complete blood count data from 09-oct-2017: no clinically important changes, all other parameters within normal limits. Urinalysis: all parameters within normal limits. In biochemistry analysis data significant were: abnormal level ALS 0.80 (0.1–0.445 mmol/h*ml) and AST 0.98 (0.1–0.68 mmol/h*ml). Lipid profile showed dyslipidemia with elevated concentrations of total cholesterol till 6.03 (normal ranges < 5.2 mmol/l), lipoproteins of low density till 4.19 mmol/l (N < 3.5), lipoproteins of high density till 1.49 mmol/l (N < 0.9), index of atherogenicity was 3.37 within normal limits < 3.0. Patient didn’t take any constant hypolipidemic therapy before hospitalization. ECG during admit ion showed sinus rhythm, HR 98 bts, ventricular extrasystolic arrhythmia, classical for chronic aneurism ST-elevation without dynamics in antero-lateral leads V2–V5 leads with T-wave inversion. In our patient chest X-ray was found enlargement of heart
shadow to the left, aorta with sclerotic changes and no mediastinum enlargement seen. Echocardiography was also made: Aorta: dilated, capsids are thickened. Ascending aorta – d 38 (20–37 mm). Aortic regurgitation I degree. Tricuspid valve – no regurgitation. Pulmonary trunk valve – no regurgitation. Pressure in pulmonary trunk is 19,0 mm Hg (< 15). Mitral valve – capsids are moderately thickened, movements of leaflets is in different direction, anterior capsid in left atrium cavity during systole, regurgitation II degree. Ejection fraction (EF) – 36 % (N – 55 % – 78 %). Function of contractility – 41 % (N – 28 % – 44 %). Left Ventricle: FDD – 53 mm (N – 35–55 mm), FSD – 42 mm (N – 23–38 mm), posterior wall thickness in systole– 12,2 mm (N – 6– 3 mm). Intraventricular septum size in diastole– 6,0 mm (6–11 mm). Additional chorda in LV cavity. In LV cavity situated round shape parietal thrombus 27*29 mm. Right Ventricle: diameter – 28,1 mm (N – 9–26 mm), wall thickness – 6,0 mm (N – 3–6 mm). Left atrium – enlarged – 44,1 mm in diameter (N – till 38 mm). Right atrium – not enlarged, 36 mm (N – 25–37). Interatrial septum – not changed, no defects. Conclusion: Sclerotic changes of aorta. Aortic regurgitation I degree. Mitral regurgitation II degree. Akinesia of LV apical segments and intraventricular septum with diastolic dysfunction of LV. Moderate dilation of left atrium. Chronic heart aneurism of LV with mural thrombus.

Abdominal ultrasound performed: Liver: Right lobe – 131 (N-till 150 mm), left lobe thickness – 64 (N-till 65 mm), moderate echogenicity, structure is homogenous. Ductular system is not changed. Gall bladder: 43*19 mm. Wall thickness is increased, normal shape. Pancreas: head – 27 mm (N – 24–30 mm), tail – 26 mm (N – 17–28), body – 24 mm (N – 12–17). Increased parenchyma echogenicity, homogenous. Ductular system is not changed. Spleen: 76*27 cm. Normal echogenicity, structure is homogenous. Right kidney: 90*45 mm, parenchyma – 17 mm, moderate echogenicity, structure is homogenous, not changed, microlithiasis. Left kidney: 91*49 mm, V = 84 cm²/c, parenchyma – 16 mm, normal echogenicity, structure is homogenous, enlarged due to pelvis dilation. Conclusion: Diffuse changes and fibrosis of pancreas parenchyma. Calculous kidney disease. Left sided pyeloectasia.

**FINAL DIAGNOSIS**


**TREATMENT RECEIVED IN HOSPITAL**

Perindopril 4 mg 1 time\day from admission, nebivolol 2,5 mg 1 time/day from admission, rosuvastatin 10 mg 1 time a day from admission, aspirin 100 mg 1 time daily from admission, fondaparinux 2,5 mg subcutaneously from admission, tiotiazolin (metabolic) 4,0 ml IV 1 time\day from admission.

**RECOMMENDATIONS**

Summarizing data from 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [9] and 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [10], the following may be applicable for our patient after discharge from hospital and for prevention of further mural thrombi formation and thromboembolic episodes appearance:

1. For mural thrombi, once diagnosed, oral anticoagulant therapy should be considered for up to 6 months, guided by repeated echocardiography and with consideration of bleeding risk and need for concomitant antiplatelet therapy [11].

2. Secondary mitral valve regurgitation: LV remodeling with lateral and apical displacement of the papillary muscles, leaflet tethering, and annular dilatation are a common cause of secondary (functional) mitral regurgitation. While transthoracic echocardiography is fundamental for the initial diagnosis, transesophageal echocardiography may be needed for better definition of the mechanism and severity of mitral regurgitation. The severity of mitral regurgitation may improve with reperfusion and aggressive medical treatment, including diuretics and arterial
vasodilators. In our patients case can be treated symptomatically without surgical correction needed [9].

3. ACE-blockers is recommended and should be up-titrated to the maximum tolerated dose, in addition to a beta-blocker, for symptomatic patients with CHF with reduced ejection fraction (HFrEF) to reduce the risk of HF hospitalization and death. A beta-blocker is recommended initially at a low dose with gradually up-titration to the maximum tolerated dose, in addition an ACE-Id or ARB if ACEIIb is not tolerated or contraindicated, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death. Beta-blockers are also effective agents for angina control in our patient’s case [10].

4. Mineralocorticoid/aldosterone receptor antagonists are recommended in all symptomatic patients (despite treatment with an ACEI and a beta-blocker) with HFrEF and LVEF ≤ 35%. Can be avoided in our patient case as EF is 36%, but used as AH treatment as needed [9, 11].

CONCLUSIONS

Left ventricular thrombus is an important complication of acute myocardial infarction that impacts embolic event risk and anticoagulant therapy. Improved understanding of post-MI thrombus in the current era is critical for optimization of diagnostic testing strategies. Advances in MI management, including prompt and effective coronary reperfusion, have yielded improvements in LV function and remodeling. Widespread use of antiplatelet agents may potentiate the benefits of reperfusion, thereby lessening the likelihood of LV thrombus.

REFERENCES